Defective interleukin 2 receptor expression is associated with the T cell disfunction subsequent to bone marrow transplantation
- 1 January 1987
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 17 (8), 1167-1174
- https://doi.org/10.1002/eji.1830170814
Abstract
In the present work we have used monoclonal antibodies (mAb) as probes to attempt a dissection of the mechanisms underlying the immunodeficiency subsequent to bone marrow transplantation (BMT). To this end we have studied 19 allogeneic BMT recipients, analyzing the proliferative response of peripheral blood mononuclear cells (PBMC) after activation with either phytohemagglutinin (PHA), anti‐CD3 or anti‐CD 2 mAb. All patients presented normal proportions of CD2+ and CD3+ lymphocytes, as assessed by flow cytometry. Our results indicated that in most cases both CD 2 and CD 3‐mediated activation pathways were inefficient to trigger normal T cell proliferation. The addition of exogenous interleukin 2 (IL 2) did not restore in most cases the proliferative response, pointing out that additional defects contribute to the hyporesponsiveness. This was more evident in the group of patients studied during the first 6 months. To further dissect the T cell defect we analyzed the effect of a phorbol ester (phorbol myristate acetate, PMA), which activates protein kinase C, on the anti‐CD 3‐induced response. Our data showed that PMA synergized with anti‐CD 3 similarly to exogenous IL 2, and restored the proliferative response only in certain cases. The expression of IL 2 receptors (CD 25) as assessed by cytofluorimetry, after either PHA or anti‐CD 3 and PMA stimulation, was shown to be depressed, and the addition of IL 2 did not restore it. Finally, we observed that the early increase of intracytoplasmic Ca2+ after anti‐CD 3 stimulation was comparable to that detected in normal PBMC. Altogether these results indicate that a diminished CD 25 expression is associated with the T cell defect, and cannot apparently be attributed to an inability of the CD 3 molecule to transduce early activation signals thus suggesting that either protein kinase C itself or an as yet undefined metabolic step preceding IL 2 receptor expression is abnormal in variable proportions of T cells after BMT, and constitutes another manifestation of this complex immunodeficiency.This publication has 39 references indexed in Scilit:
- Involvement of the CD4 molecule in a post‐activation event on T cell proliferationEuropean Journal of Immunology, 1987
- Protein kinase C activation by diacylglycerol second messengersCell, 1986
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Anti‐CD2 (sheep red blood cell receptor) monoclonal antibodies and T cell activation I. Pairs of anti‐T11.1 and T11.2 (CD2 subgroups) are strongly mitogenic for T cells in presence of 12‐O‐tetradecanoylphorbol 13‐acetateEuropean Journal of Immunology, 1986
- The Human T-Cell ReceptorAnnual Review of Immunology, 1984
- RECOVERY OF IN VIVO CELLULAR IMMUNITY AFTER HUMAN MARROW GRAFTINGTransplantation, 1984
- Improved survival following bone marrow transplantation for aplastic anaemiaBritish Journal of Haematology, 1983
- Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution.The Journal of Experimental Medicine, 1983
- Calcium homeostasis in intact lymphocytes: cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator.The Journal of cell biology, 1982
- Human cytotoxic T cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis‐inhibiting effect of 7 monoclonal antibodiesEuropean Journal of Immunology, 1982